Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 56Prostatic Neoplasms 46Glioblastoma 28Brain Neoplasms 25Neoplasms 23Glioma 20Carcinoma, Non-Small-Cell Lung 19Lung Neoplasms 18Carcinoma, Hepatocellular 14Gliosarcoma 13Colorectal Neoplasms 12Uterine Cervical Neoplasms 11Neoplasm Metastasis 11Rectal Neoplasms 10Lymphoma, Non-Hodgkin 10Oligodendroglioma 9Melanoma 9Central Nervous System Neoplasms 9Astrocytoma 9Lymphoma 8Head and Neck Neoplasms 8Esophageal Neoplasms 8Colonic Neoplasms 8Ependymoma 7Squamous Cell Carcinoma of Head and Neck 6Pancreatic Neoplasms 6Lymphoma, Large B-Cell, Diffuse 6Carcinoma, Renal Cell 6Breast Neoplasms, Male 6Ovarian Neoplasms 5

Interventions

Nivolumab 13Surveys and Questionnaires 6Ipilimumab 6linrodostat 5Standard of Care 5Paclitaxel 5Bevacizumab 5Sirolimus 4Pemetrexed 4Interviews as Topic 4Gemcitabine 4Docetaxel 4ARRY-334543 4temsirolimus 3relatlimab 3Erlotinib Hydrochloride 3Cetuximab 3Carboplatin 3regorafenib 2anlotinib 2abemaciclib 2Vorinostat 2Trastuzumab 2Sorafenib 2N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2Magnetic Resonance Spectroscopy 2Doxorubicin 2Dasatinib 2Cyclophosphamide 2vorolanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Advanced Cancer × Magnetic Resonance Spectroscopy × Clear all
NCT01143779 2022-01-04

FLT-PET as an Imaging Biomarker With Temsirolimus, Topotecan, and Bortezomib

M.D. Anderson Cancer Center

Phase 1 Completed
3 enrolled

Advanced Cancer

NCT00610493 2017-12-08

Bevacizumab and Temsirolimus in Patients With Advanced Malignancy

M.D. Anderson Cancer Center

Phase 1 Completed
193 enrolled

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡